The utility of Schlafen 11 (SLFN11) expression as a predictive biomarker for platinum-based chemotherapy has been established for cancers from different histologies. However, the therapeutic relevance of SLFN11 in bladder cancer (BC) is unknown.
The utility of Schlafen 11 (SLFN11) expression as a predictive biomarker for platinum-based chemotherapy has been established for cancers from different histologies. However, the therapeutic relevance of SLFN11 in bladder cancer (BC) is unknown.
Purpose: To assess the association of adverse pathology (AP), defined as high-grade (≥ Gleason Grade Group 3) and/or non-organ confined disease, with long-term oncologic outcomes after radical prostatectomy (RP).
Purpose: To assess the association of adverse pathology (AP), defined as high-grade (≥ Gleason Grade Group 3) and/or non-organ confined disease, with long-term oncologic outcomes after radical prostatectomy (RP).
–Results strongly support the use of the Oncotype DX® GPS™ test, the only genomic assay that reports individual values for adverse pathology risk, consistent with the new study findings– San Francisco, CA (UroToday.com) — Exact Sciences Corp., a global leader in cancer diagnostics, announced the publication of results underscoring the importance of adverse pathology as a reliable […]
–Results strongly support the use of the Oncotype DX® GPS™ test, the only genomic assay that reports individual values for adverse pathology risk, consistent with the new study findings– San Francisco, CA (UroToday.com) — Exact Sciences Corp., a global leader in cancer diagnostics, announced the publication of results underscoring the importance of adverse pathology as a reliable […]
San Francisco, CA (UroToday.com) — Movember is launching the world’s largest prostate cancer and testicular clinical and research network, aimed at improving the overall survival and quality of life for those living with diseases that affect over 1.4 million men worldwide every year.
San Francisco, CA (UroToday.com) — Movember is launching the world’s largest prostate cancer and testicular clinical and research network, aimed at improving the overall survival and quality of life for those living with diseases that affect over 1.4 million men worldwide every year.
Background: Toileting behaviors are increasingly recognized as factors potentially contributing to development of lower urinary tract symptoms (LUTS).
Background: Toileting behaviors are increasingly recognized as factors potentially contributing to development of lower urinary tract symptoms (LUTS).
